Amgen Presents at Morgan Stanley Global Healthcare Conference Tuesday With Jay Bradner (EVP R&D + AI) and Thomas Dittrich (CFO); MariTide Extended-Dosing Positioning Continues Following Last Week's Wells Fargo Conference
Amgen (NASDAQ: AMGN) presented Tuesday September 15, 2026 at 11:30 a.m. ET at the Morgan Stanley 24th Annual Global Healthcare Conference in New York with Jay Bradner MD (Executive Vice President Research and Development, Artificial Intelligence and Data) and Thomas Dittrich (Executive Vice President and CFO) — an unusual R&D-plus-finance pairing that indicates the AI-driven research investment thesis is a live investor question alongside the near-term MariTide (maridebart cafraglutide, antibody-peptide conjugate combining GLP-1 receptor agonism with GIP receptor antagonism) obesity narrative. The Wells Fargo Healthcare Conference presentation last Thursday September 10 laid out the MariTide dosing thesis (8-week or quarterly maintenance dosing, 4-6 doses per year after induction) plus the MARITIME-SWITCH Phase 3 conversion trial from weekly injectable semaglutide or tirzepatide onto monthly MariTide. Phase 2 data anchored 20% weight loss at 52 weeks plus reductions in triglycerides, hs-CRP, and an 11 mmHg blood pressure drop. Bradner is also expected to address the pipeline consolidation following the August discontinuation of AMG 513 (Phase 1 obesity), which left MariTide as the sole late-stage Amgen obesity asset. Filing is planned late 2026 to early 2027 with anticipated launch 2027-2028.